These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
380 related articles for article (PubMed ID: 28454983)
21. Review. Neurobiological mechanisms for opponent motivational processes in addiction. Koob GF; Le Moal M Philos Trans R Soc Lond B Biol Sci; 2008 Oct; 363(1507):3113-23. PubMed ID: 18653439 [TBL] [Abstract][Full Text] [Related]
22. Neurochemical Evidence of Preclinical and Clinical Reports on Target-Based Therapy in Alcohol Used Disorder. Prajapati SK; Bhaseen S; Krishnamurthy S; Sahu AN Neurochem Res; 2020 Feb; 45(2):491-507. PubMed ID: 31898084 [TBL] [Abstract][Full Text] [Related]
23. Drug addiction co-morbidity with alcohol: Neurobiological insights. McGinn MA; Pantazis CB; Tunstall BJ; Marchette RCN; Carlson ER; Said N; Koob GF; Vendruscolo LF Int Rev Neurobiol; 2021; 157():409-472. PubMed ID: 33648675 [TBL] [Abstract][Full Text] [Related]
30. The neurobiology of addiction: a neuroadaptational view relevant for diagnosis. Koob GF Addiction; 2006 Sep; 101 Suppl 1():23-30. PubMed ID: 16930158 [TBL] [Abstract][Full Text] [Related]
31. Glutamatergic plasticity and alcohol dependence-induced alterations in reward, affect and cognition. Burnett EJ; Chandler LJ; Trantham-Davidson H Prog Neuropsychopharmacol Biol Psychiatry; 2016 Feb; 65():309-20. PubMed ID: 26341050 [TBL] [Abstract][Full Text] [Related]
32. Neurocircuitry targets in ethanol reward and dependence. Koob GF; Roberts AJ; Schulteis G; Parsons LH; Heyser CJ; Hyytiä P; Merlo-Pich E; Weiss F Alcohol Clin Exp Res; 1998 Feb; 22(1):3-9. PubMed ID: 9514280 [TBL] [Abstract][Full Text] [Related]
33. Dissociating Motivational From Physiological Withdrawal in Alcohol Dependence: Role of Central Amygdala κ-Opioid Receptors. Kissler JL; Walker BM Neuropsychopharmacology; 2016 Jan; 41(2):560-7. PubMed ID: 26105136 [TBL] [Abstract][Full Text] [Related]
34. Advances in the characterization of negative affect caused by acute and protracted opioid withdrawal using animal models. Ozdemir D; Allain F; Kieffer BL; Darcq E Neuropharmacology; 2023 Jul; 232():109524. PubMed ID: 37003572 [TBL] [Abstract][Full Text] [Related]
35. The dark side of emotion: the addiction perspective. Koob GF Eur J Pharmacol; 2015 Apr; 753():73-87. PubMed ID: 25583178 [TBL] [Abstract][Full Text] [Related]
36. Pre-clinical evidence that corticotropin-releasing factor (CRF) receptor antagonists are promising targets for pharmacological treatment of alcoholism. Lowery EG; Thiele TE CNS Neurol Disord Drug Targets; 2010 Mar; 9(1):77-86. PubMed ID: 20201818 [TBL] [Abstract][Full Text] [Related]
37. Epigenetic basis of the dark side of alcohol addiction. Pandey SC; Kyzar EJ; Zhang H Neuropharmacology; 2017 Aug; 122():74-84. PubMed ID: 28174112 [TBL] [Abstract][Full Text] [Related]
38. Anxiety during abstinence from alcohol: A systematic review of rodent and human evidence for the anterior insula's role in the abstinence network. Flook EA; Luchsinger JR; Silveri MM; Winder DG; Benningfield MM; Blackford JU Addict Biol; 2021 Mar; 26(2):e12861. PubMed ID: 31991531 [TBL] [Abstract][Full Text] [Related]
39. Alcohol Use Disorder Treatment: Problems and Solutions. Koob GF Annu Rev Pharmacol Toxicol; 2024 Jan; 64():255-275. PubMed ID: 38261428 [TBL] [Abstract][Full Text] [Related]